背景介绍 Unlike treatment with AZD 2281 (Olaparib, Axon 1464), AZD 2461 succesfully circumvents drug resistance of Pgp-proficient tumors, and inactivation of p53-binding protein 1 (53BP1) as a causal factor in PARPi resistance. 产品介绍 AZD2461 is a novel PARP inhibitor with low affinity for than Olaparib. AZD2641 is currently in Phase I clinical studies to treat solid tumors.